FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2622274629> ?p ?o ?g. }

• W2622274629 endingPage "55" @default.
• W2622274629 startingPage "45" @default.
• W2622274629 abstract "Purpose For early-stage Hodgkin lymphoma (HL), optimal chemotherapy regimen and the number of cycles to be delivered remain to settle down. The H9-U trial compared three modalities of chemotherapy followed by involved-field radiotherapy (IFRT) in patients with stage I-II HL and risk factors (NCT00005584). Patients and methods Patients aged 15–70 years with untreated supradiaphragmatic HL with at least one risk factor (age ≥ 50, involvement of 4–5 nodal areas, mediastinum/thoracic ratio ≥ 0.35, erythrocyte sedimentation rate (ESR) ≥ 50 without B-symptoms or ESR ≥ 30 and B-symptoms) were eligible for the randomised, open label, multicentre, non-inferiority H9-U trial. The limit of non-inferiority was set at 10% for the difference between 5-year event-free survival (EFS) estimates. From October 1998 to September 2002, 808 patients were randomised to receive either the control arm 6-ABVD-IFRT (n = 276), or one of the two experimental arms: 4-ABVD-IFRT (n = 277) or 4-BEACOPPbaseline-IFRT (n = 255). Results Results in the 4-ABVD-IFRT (5-year EFS, 85.9%) and the 4-BEACOPPbaseline-IFRT (5-year EFS, 88.8%) were not inferior to 6-ABVD-IFRT (5-year EFS, 89.9%): difference of 4.0% (90%CI, -0.7%–8.8%) and of 1.1% (90%CI,-3.5%–5.6%) respectively. The 5-year overall survival estimates were 94%, 93%, and 93%, respectively. Patients treated with combined modality treatment chemotherapeutic regimen comprising doxorubicin (Adriamycin), bleomycin, vincristine (Oncovin), cyclophosphamide, procarbazine, etoposide and prednisone (BEACOPP)baseline more often developed serious adverse events requiring supportive measures and hospitalisation compared with patients receiving the chemotherapeutic regimen comprising doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD). Conclusions The trial demonstrates that 4-ABVD followed by IFRT yields high disease control in patients with early-stage HL and risk factors responding to chemotherapy. Although non-inferior in terms of efficacy, four cycles of BEACOPPbaseline were more toxic than four or six cycles of ABVD." @default.
• W2622274629 created "2017-06-15" @default.
• W2622274629 creator A5000000264 @default.
• W2622274629 creator A5005804337 @default.
• W2622274629 creator A5006682547 @default.
• W2622274629 creator A5009172923 @default.
• W2622274629 creator A5011615789 @default.
• W2622274629 creator A5014942120 @default.
• W2622274629 creator A5017396423 @default.
• W2622274629 creator A5022075377 @default.
• W2622274629 creator A5023165076 @default.
• W2622274629 creator A5023992858 @default.
• W2622274629 creator A5024260899 @default.
• W2622274629 creator A5026185552 @default.
• W2622274629 creator A5027520859 @default.
• W2622274629 creator A5030988280 @default.
• W2622274629 creator A5033149886 @default.
• W2622274629 creator A5035332783 @default.
• W2622274629 creator A5045767165 @default.
• W2622274629 creator A5052452447 @default.
• W2622274629 creator A5056514957 @default.
• W2622274629 creator A5062305482 @default.
• W2622274629 creator A5064102980 @default.
• W2622274629 creator A5069105295 @default.
• W2622274629 creator A5070508738 @default.
• W2622274629 creator A5081216142 @default.
• W2622274629 creator A5081879832 @default.
• W2622274629 creator A5085665866 @default.
• W2622274629 creator A5086354986 @default.
• W2622274629 creator A5090326578 @default.
• W2622274629 creator A5091416702 @default.
• W2622274629 date "2017-08-01" @default.
• W2622274629 modified "2023-10-10" @default.
• W2622274629 title "ABVD or BEACOPP baseline along with involved-field radiotherapy in early-stage Hodgkin Lymphoma with risk factors: Results of the European Organisation for Research and Treatment of Cancer (EORTC)–Groupe d'Étude des Lymphomes de l'Adulte (GELA) H9-U intergroup randomised trial" @default.
• W2622274629 cites W1825210192 @default.
• W2622274629 cites W1942259007 @default.
• W2622274629 cites W1979128420 @default.
• W2622274629 cites W2007239126 @default.
• W2622274629 cites W2025318905 @default.
• W2622274629 cites W2039888190 @default.
• W2622274629 cites W2044479160 @default.
• W2622274629 cites W2076334524 @default.
• W2622274629 cites W2101472190 @default.
• W2622274629 cites W2114574605 @default.
• W2622274629 cites W2115919161 @default.
• W2622274629 cites W2125790189 @default.
• W2622274629 cites W2127055058 @default.
• W2622274629 cites W2156613346 @default.
• W2622274629 cites W2163695063 @default.
• W2622274629 cites W2171187650 @default.
• W2622274629 cites W2320759023 @default.
• W2622274629 cites W2596050027 @default.
• W2622274629 doi "https://doi.org/10.1016/j.ejca.2017.05.005" @default.
• W2622274629 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28601705" @default.
• W2622274629 hasPublicationYear "2017" @default.
• W2622274629 type Work @default.
• W2622274629 sameAs 2622274629 @default.
• W2622274629 citedByCount "27" @default.
• W2622274629 countsByYear W26222746292017 @default.
• W2622274629 countsByYear W26222746292018 @default.
• W2622274629 countsByYear W26222746292019 @default.
• W2622274629 countsByYear W26222746292020 @default.
• W2622274629 countsByYear W26222746292021 @default.
• W2622274629 countsByYear W26222746292022 @default.
• W2622274629 countsByYear W26222746292023 @default.
• W2622274629 crossrefType "journal-article" @default.
• W2622274629 hasAuthorship W2622274629A5000000264 @default.
• W2622274629 hasAuthorship W2622274629A5005804337 @default.
• W2622274629 hasAuthorship W2622274629A5006682547 @default.
• W2622274629 hasAuthorship W2622274629A5009172923 @default.
• W2622274629 hasAuthorship W2622274629A5011615789 @default.
• W2622274629 hasAuthorship W2622274629A5014942120 @default.
• W2622274629 hasAuthorship W2622274629A5017396423 @default.
• W2622274629 hasAuthorship W2622274629A5022075377 @default.
• W2622274629 hasAuthorship W2622274629A5023165076 @default.
• W2622274629 hasAuthorship W2622274629A5023992858 @default.
• W2622274629 hasAuthorship W2622274629A5024260899 @default.
• W2622274629 hasAuthorship W2622274629A5026185552 @default.
• W2622274629 hasAuthorship W2622274629A5027520859 @default.
• W2622274629 hasAuthorship W2622274629A5030988280 @default.
• W2622274629 hasAuthorship W2622274629A5033149886 @default.
• W2622274629 hasAuthorship W2622274629A5035332783 @default.
• W2622274629 hasAuthorship W2622274629A5045767165 @default.
• W2622274629 hasAuthorship W2622274629A5052452447 @default.
• W2622274629 hasAuthorship W2622274629A5056514957 @default.
• W2622274629 hasAuthorship W2622274629A5062305482 @default.
• W2622274629 hasAuthorship W2622274629A5064102980 @default.
• W2622274629 hasAuthorship W2622274629A5069105295 @default.
• W2622274629 hasAuthorship W2622274629A5070508738 @default.
• W2622274629 hasAuthorship W2622274629A5081216142 @default.
• W2622274629 hasAuthorship W2622274629A5081879832 @default.
• W2622274629 hasAuthorship W2622274629A5085665866 @default.
• W2622274629 hasAuthorship W2622274629A5086354986 @default.
• W2622274629 hasAuthorship W2622274629A5090326578 @default.
• W2622274629 hasAuthorship W2622274629A5091416702 @default.
• W2622274629 hasBestOaLocation W26222746292 @default.
• W2622274629 hasConcept C126322002 @default.
• W2622274629 hasConcept C141071460 @default.

• next